The app, called Rejoyn, is cleared as a supplement to currently approved therapies and works by using specifically designed ...

Addition of the antipsychotic lumateperone (Caplyta) to an existing antidepressant improved symptoms of depression in a ...

especially treatment-resistant depression. Of the nearly 9 million people with major depression in the United States who have ...

Researchers found that a 10-week course of home-based transcranial direct current stimulation (tDCS) significantly improved ...

David Walt, the Hansjörg Wyss Professor of Bioinspired Engineering at HMS and professor of pathology at Brigham and Women’s Hospital, is operating at a microscopic level, observing cell abnormalities ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...

If you’re feeling depressed and looking for a solution, there are many options: medications, CBT, DBT, somatic therapy and so ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...

Patients with comorbid depression and insomnia do not feel satisfied by their health care providers or available treatment options.

Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning ...

Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the ...